Q-omics provides the consensus-scored TMBIM4 profile across patient tissues and cancer cell-line models. TMBIM4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TMBIM4 is differentially expressed in 11, with the highest sampling consensus in LUSC. Additionally, TMBIM4 RNA expression shows 19,344 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and LUSC as cancer lineages where TMBIM4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMBIM4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMBIM4 survival associations across molecular data types. TMBIM4 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMBIM4 RNA expression–survival associations across cancer types. High TMBIM4 expression shows unfavorable associations in UVM, LGG, GBM and LIHC, but favorable associations in MESO and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TMBIM4 RNA expression.
This table summarizes TMBIM4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for TMBIM4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMBIM4 shows lower tumor expression in LUSC, KICH, UCEC, COAD and LUAD and higher tumor expression in LIHC. The LUSC box plot shows higher TMBIM4 RNA expression in normal versus tumor tissue (log2 FC = −1.664, t-test p < 0.001).
This table shows molecular features associated with TMBIM4 in patient tissues and cancer cell lines. In patient samples, TMBIM4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMBIM4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
